Day: April 9, 2024

First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control EDEN PRAIRIE, Minn., April 09, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first implant of its OneRF™ Ablation electrode by doctors at a top ranked hospital in the US, as ranked by the US News & World Best Hospital Report in its 2023-2024 publication. The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures. “We...

The Nelk Boys, a widely followed YouTube and social media entertainment groups, join Safety Shot as brand ambassadors With over 10 million subscribers across their channels on YouTube, more than 1.6 billion views, and 4.3 million followers on Instagram, the Nelk Boys are some of the most recognizable internet personalities in North America Safety Shot — Extend the night, enhance the morningJUPITER, FL, April 09, 2024 (GLOBE NEWSWIRE) — Safety Shot, Inc. (Nasdaq: SHOT) today announced that the Nelk Boys have joined forces with Safety Shot as brand ambassadors. The Nelk Boys are an entertainment and retail company with YouTube channels under brands including NELK and Full Send that feature prank videos and high profile guests like Elon Musk, Donald Trump, and Mike Tyson. The Nelk Boys have popularized and trademarked the term...

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) — Stronghold Digital Mining, Inc. (NASDAQ: SDIG) (“Stronghold” or the “Company”) today provided the following updates regarding its operations and financial performance: Bitcoin Mining Update Stronghold mined 179 Bitcoin in March 2024 and generated approximately $0.1 million in energy revenue, which represents the equivalent of approximately one additional Bitcoin based on the average price of Bitcoin during the month. This equates to approximately 180 of Bitcoin-equivalent production in March 2024, up approximately 4% from 173 Bitcoin-equivalent production in February 2024. The Company generated an estimated $11.1 million of revenue during March, an increase of 37% and 94% compared to February 2024 and March 2023, respectively. The primary driver of the sequential increase was a higher...

Completed Two Investments in New and Existing Portfolio Companies Representing $25.0 Million in Funded Loans MENLO PARK, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the first quarter ended March 31, 2024. “In the first quarter, we saw heightened pipeline activity and executed on investments that demonstrate our disciplined lending strategy to attractive late and growth stage companies,” said Greg Greifeld, Acting Chief Executive Officer of Runway Growth, and Deputy Chief Investment Officer and Head of Credit of Runway Growth Capital LLC. “We are focused on prudently deploying...

PALM BEACH GARDENS, Fla., April 09, 2024 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) announced today the commencement of an underwritten public offering of unsecured notes due 2029 (the “Notes”). The Notes are expected to be listed on The Nasdaq Global Market under the trading symbol “GECCI,” and to trade thereon within 30 days from the original issue date. The interest rate and other terms of the Notes will be determined by negotiations between the Company and the underwriters. The Company expects to use the net proceeds from the offering for general corporate purposes, including making investments consistent with its investment objectives, and may also elect to (i) redeem a portion of its outstanding $45.6 million aggregate principal amount of 6.75% unsecured notes due 2025, (ii) redeem...

Distributors in China and Japan have each maintained exclusive distribution agreements with the Company for over 10 years and collectively accounted for 46% of the Company’s total international revenue in 2023 HORSHAM, Pa., April 09, 2024 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the renewal of two distinct distribution agreements in international territories – one with the current exclusive distributor in China and a second with the current exclusive distributor in Japan. Terms of each of the distribution agreements are for three years and carry minimum unit placements and/or purchases of the XTRAC and VTRAC devices. “The...

ENCINO, Calif., April 09, 2024 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), the global leader in delivering state-of-the-art solutions for the asset finance and leasing industry, has announced the go-live of its next-generation platform NFS Ascent for a leading German auto captive finance company and longstanding client to support their operations in South Korea. This deployment consisted of the full NFS Ascent suite, which includes both the Retail and the Wholesale platforms. The NFS Ascent Retail platform includes Omni Point of Sale (Omni POS) and Contract Management System (CMS), while Ascent’s Wholesale Finance System is part of its Wholesale platform. These deployments are part of a contract with a total value in excess of $110 million – the largest contract in NETSOL’s history. The initial agreement was signed...

BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1, the Company’s lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults. LSTA1 recently received Rare Pediatric Disease Designation for osteosarcoma, as announced by the Company on March 21, 2024. “We are thrilled to have received another favorable regulatory designation from the FDA. This underscores the significant unmet medical need and demand for better treatments for...

Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease Experts will explain pathophysiology of PH-HFpEF, and mechanistic rationale for levosimendan Update on the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for the treatment of PH-HFpEF Tenax to Host Webcast on Thursday, April 18, 2024, at 10:00 am ET CHAPEL HILL, N.C., April 09, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet...

SPARTANBURG, S.C., April 09, 2024 (GLOBE NEWSWIRE) — Denny’s Corporation (the “Company”) (NASDAQ: DENN), owner and operator of Denny’s Inc. (“Denny’s”) and Keke’s Inc. (“Keke’s”), will announce financial and operating results for its first quarter ended March 27, 2024, on Tuesday, April 30, 2024, after the markets close. Senior management will hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and answer questions. Interested parties are invited to listen to a live broadcast of the conference call accessible through the Investor Relations section of the Company’s website at investor.dennys.com. For any questions, please contact the Company’s Investor Relations Department at 877-784-7167. About Denny’s Corporation Denny’s Corporation...